Taking place in Boston (August 17–19, 2026), the 5th Oligonucleotide Analytical Development & CMC Summit is a premier event dedicated to advancing analytical and CMC strategies for oligonucleotide therapeutics. Bringing together experts from Alnylam, Biogen, Ionis Pharmaceuticals, Amgen, and Avidity Biosciences, the meeting tackles key challenges in impurity control, complex chemistries, and scalable manufacturing. Attendees will gain insights into cutting-edge analytical tools including mass spectrometry and sequencing, alongside evolving global regulatory expectations. Covering modalities such as ASOs, siRNA, and conjugates, the summit provides practical frameworks to improve product quality, comparability, and regulatory readiness. Connect with 90+ industry leaders and accelerate development from early-stage research through to commercialization. Visit the website for more information.

To learn more and register online, please visit: https://ter.li/l10canku